NEW YORK, Sept. 12, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and emerging human health threats, today announced the receipt of a Small Business Innovation Research Advanced Technology Phase I grant from the National Institute of Allergy and Infectious Disease (SBIR-AT-NIAID). NIAID is part of the National Institutes of Health (NIH), and its grants are typically given to high-priority NIH programs.
